Vaccine For Monkeypox
There are two types of vaccines for monkeypox. ACAM2000 is designed to be given in one dose, while the second generation, called Jynneos, requires two doses, with 28 days between each. A single dose of either vaccine may not be effective enough to prevent the infection within four days after exposure. This is because there is no way to determine whether a vaccine will prevent the disease.
The disease was first identified in 1958 among research monkeys and was only first reported in humans in 1970 in the Democratic Republic of Congo. It is caused by a DNA virus, not the COVID virus, and it is not spread through skin-to-skin contact. There are two distinct strains of monkeypox virus, with the Central African clade being more severe than the West African one.
Currently, there is only a small supply of JYNNEOS vaccine available in the United States. However, more vaccine is expected in the coming weeks and months. The CDC is committed to distributing the vaccine evenly. The vaccine is licensed for post-exposure prophylaxis and is distributed through the National Strategic Stockpile. If you are at risk for monkeypox, get the vaccine.
The Biden administration has also taken steps to expand the availability of monkeypox testing. Recently, the CDC announced collaborations with five private companies that will offer monkeypox testing. Despite these advances, people who haven’t received the vaccine have still contracted the disease. In a recent case, Michael Austin Nicolo, a New York bartender, contracted monkeypox from a rogue monkey and became ill. The infection has affected more than 1,000 people across the US this year. In addition, many people have been unable to find the monkeypox vaccine.
The virus responsible for monkeypox is endemic in Africa. It is primarily found in Central Africa and causes 1% to 10% of deaths. However, monkeypox outbreaks in the United States are rare. Usually, the virus only appears on humans for two to four weeks. There is currently no vaccine for monkeypox in the US, but it is recommended for high risk individuals. In cases where monkeypox is present, there are precautionary measures people can take to prevent exposure.
A few countries have recently confirmed cases of monkeypox. These cases have raised questions about vaccine availability in countries with high monkeypox outbreaks. While the virus is endemic in Africa, the United States and Europe have seen cases in recent years. This disease is not common in the United States but it is a concern for the public. If you or someone you know suffers from monkeypox, it is important to seek the proper vaccination.
The Biden-Harris Administration has a new monkeypox vaccine strategy and an updated version of JYNNEOS for those with high-risk of exposure to the virus. Although there is already a vaccine for monkeypox, it is not widely available. The biden-Harris administration is investing in research and development of a vaccine. The vaccine JYNNEOS was administered to both patients within 36 hours.
The latest outbreak of monkeypox has led to the order of millions of doses of the Jynneos vaccine by Bavarian Nordic. It is expected to be available in 2019. In cases where monkeypox is already endemic in the United States, an ACAM2000 vaccine has been approved. The vaccine is not available for the general public and has not yet been approved by the U.S. government.
Symptoms of the illness vary, but can include flu-like symptoms and swollen lymph nodes. The rash looks like pimples and blisters and goes through several stages before healing. Monkeypox can be fatal if left untreated. While vaccination is not recommended for routine immunity, the Health Department may recommend it in cases of high exposure to monkeypox. If you are concerned, consult a doctor.
